Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
RESEARCH TOOLSreports
Holding GLUE?
Track your performance easily
See the Price Targets and Ratings of:
GLUE Analyst Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GLUE Stock 12 Month Forecast
Average Price Target
$15.25
▲(120.06% Upside)
| Highest Price Target$20.00 | Average Price Target$15.25 | Lowest Price Target$11.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Wells Fargo
Downgraded
12/19/24
TD Cowen
Reiterated
12/06/24
Piper Sandler
Reiterated
12/06/24
J.P. Morgan
Reiterated
11/08/24
Wedbush
Reiterated
10/28/24
Guggenheim
―
Buy
―
Reiterated
06/27/24
We spoke with management who noted that the company is encouraged by the initial assessment of the 0.5 mg dose of off schedule (21/7), which could be a potl. recommended Phase II dose (RP2D) and are now evaluating a 0.75mg 21/7 schedule with a final RP2D determination and data presentation anticipated in 2H24. Recall, MRT-2359 is being developed as a potential first-in-class therapy for patients with MYC-driven cancers, including NSCLC (also see here). MRT-6160 is a potent, selective, and orally bioavailable degrader of VAV1, expressed in T and B cells and a potential new target for autoimmune diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), multiple sclerosis (MS), and dermatological disorders. GLUE is on track to initiate a Ph. I SAD/ MAD study this summer, with initial trial results guided to Q1 2025.
Unknown Analyst
Not Ranked
UBS
$22→$20
Buy
188.60%
Upside
Reiterated
04/29/24
Monte Rosa Therapeutics (GLUE) PT Lowered to $20 at UBSUBS lowered its price target on Monte Rosa Therapeutics (NASDAQ: GLUE) to $20.00 (from $22.00) while maintaining a Buy rating.
Best Analysts Covering Monte Rosa Therapeutics
Which Analyst Should I Follow If I Want to Buy GLUE and Sell After:
1 Month
xxx
Success Rate
5/7 ratings generated profit
Average Return
+20.69%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +20.69% per trade.
3 Months
xxx
Success Rate
7/11 ratings generated profit
Average Return
+5.48%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +5.48% per trade.
1 Year
Success Rate
4/7 ratings generated profit
Average Return
+30.70%
reiterated a buy rating 16 days ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +30.70% per trade.
2 Years
xxx
Success Rate
4/7 ratings generated profit
Average Return
+15.83%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +15.83% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GLUE Analyst Recommendation Trends
Rating
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
8
7
6
5
5
Buy
3
3
1
2
3
Hold
0
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
10
7
7
9
Each month's total comprises the sum of three months' worth of ratings.
GLUE Financial Forecast
GLUE Stock Forecast FAQ
What is GLUE’s average 12-month price target, according to analysts?
Based on analyst ratings, Monte Rosa Therapeutics’s 12-month average price target is $15.25.
What is GLUE’s upside potential, based on the analysts’ average price target?
Monte Rosa Therapeutics has 120.06% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GLUE a Buy, Sell or Hold?
Monte Rosa Therapeutics has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
What is Monte Rosa Therapeutics’s price target?
The average price target for Monte Rosa Therapeutics is $15.25. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $11.00. The average price target represents 120.06% Increase from the current price of $6.93.
The highest analyst price target is $20.00 ,the lowest forecast is $11.00. The average price target represents 120.06% Increase from the current price of $6.93.
What do analysts say about Monte Rosa Therapeutics?
Monte Rosa Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of GLUE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.